Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. Safety, tolerability, immunogenicity, and PK/PD will be measured. To evaluate feasibility of the endpoints, additional endpoints of ALSFRS-R, respiratory function tests, disease biomarkers and patient-reported outcomes will be measured.

Study Overview

• Status: Completed
• Conditions: Motor Neuron Disease; Amyotrophic Lateral Sclerosis
• Intervention / Treatment: Biological: IC14

Detailed Description

The objectives of this study are to determine:

• The safety, tolerability and immunogenicity of IC14 in patients with motor neurone disease (MND).
• The pharmacokinetics and pharmacodynamics of IC14 in patients with MND.
• The preliminary effect of IC14 on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) in patients with MND.
• The preliminary effect of IC14 on forced vital capacity (FVC) and other clinical markers of disease severity in patients with MND.
• The preliminary effect of IC14 on patient-reported outcome measures.
• The preliminary effect of IC14 on disease biomarkers.

Ten patients with MND will be sequentially assigned to receive one of two dose regimens of IC14 in an unblinded manner:

• For the initial 3 patients: IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses.
• For the subsequent 7 patients: IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 for 4 total doses.

Study participation will continue until 28 days after the last dose of study drug.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Herston, Queensland, Australia, 4006
      • Royal Brisbane and Women's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

A patient must fulfill all of the following criteria to be eligible for enrollment:

1. Signed informed consent prior to initiation of any study-specific procedures.
2. Familial or sporadic motor neurone disease (MND) defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations.
3. First symptoms of MND within 3 years of informed consent.
4. Age between 18 and 75 years at time of informed consent.
5. Seated Forced Vital Capacity (FVC) ≥ 65% of predicted value.
6. Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to screening visit.

7. Adequate bone marrow reserve, renal and liver function:

   • absolute neutrophil count ≥ 1500/µL
   • lymphocyte count < 48%
   • platelet count ≥ 150,000/µL
   • hemoglobin ≥ 11 g/dL
   • Estimated glomerular filtration rate (eGFR) >= 40 mL/min/1.73 m2
   • Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) ≤ 2x upper imit of normal (ULN), total bilirubin ≤ 1.5x ULN
   • serum albumin ≥ 2.8 g/dL

8. Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods:

   • Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
   • Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
   • Stable hormonal contraception for at least 3 months prior to study through study completion; or
   • Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
9. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.
10. Males with female partners of childbearing potential must use contraception through study completion.
11. Medically safe to have lumbar puncture to collect cerebrospinal fluid.
12. Able to give informed consent and able to comply with all study visits and all study procedures.

Exclusion Criteria:

A patient fulfilling any of the following criteria at screening is to be excluded from enrollment in the study:

1. Dependence on mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening.
2. Treatment with a drug or device within the last 30 days that has not received regulatory approval.
3. Treatment within 12 months with immunomodulator or immunosuppressant agent (including but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation).
4. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks.
5. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.

6. Presence of any of the following clinical conditions:

   • Bleeding diathesis or receipt of anticoagulants within 7 days (or any other clinical condition that would, in the opinion of the investigator, place the patient at increased risk during lumbar puncture).
   • History of one or more of the following: cardiac insufficiency (New York Heart Association [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg).
   • History of venous thromboembolic disease within 12 months, myocardial infarction, or cerebrovascular accident.
   • Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.
   • Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis.
   • Evidence of active malignant disease, malignancies diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma).
   • Human immunodeficiency virus infection or other immunodeficiency illness.
   • Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days.
   • Drug abuse or alcoholism within the past 12 months.
   • Significant neuromuscular disease other than MND.
   • Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, hepatitis B virus (HBV), or hepatitis C (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy.
7. Pregnancy or breastfeeding.
8. Deprivation of freedom by administrative or court order.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IC14 dose level 1; For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses	Biological: IC14; chimeric monoclonal antibody against human IC14; Other Names: monoclonal antibody against CD14
Experimental: IC14 dose level 2; For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4	Biological: IC14; chimeric monoclonal antibody against human IC14; Other Names: monoclonal antibody against CD14

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent adverse events (safety, tolerability)	Number of participants with treatment-emergent adverse events (safety, tolerability) classified by MedDRA	one month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-related change in ALSFRS-R functional scale	Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) [0 (worst) to 48 (best)]	one month
Respiratory function	Treatment-related change in percent normal Forced Vital Capacity [0% (worst) to 100% (best)]	one month
Muscle function	Treatment-related change in percent normal Sniff Nasal Pressure [0% (worst) to 100% (best)]	one month
Quality of life measured by ALSSQOL	Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised (ALSSQOL-R) [0 (worst) to 460 (best)]	one month
Patient-reported outcome	Treatment-related change Edinburgh Cognitive and Behavioural Assessment Score (ECAS) [0 (worst) to 136 (best)]	one month
Maximum Plasma Concentration (Cmax)	Maximum serum IC14 concentration (micrograms per milliliter)	one month
Area Under the Curve (AUC)	Area Under the Curve for serum IC14 (microgram x hr/mL)	one month
Monocyte CD14 Receptor Occupancy	Treatment-related change in percent monocyte CD14 receptor occupancy as a pharmacodynamic marker	one month
Urinary p75 neurotrophin receptor (biomarker)	Treatment-related change in urinary concentration of urinary p75 neurotrophin receptor (NTR) (nanograms per milligram creatinine)	one month
Neurofilament (biomarker)	Treatment-related change in concentration of neurofilament (picograms per milliliter)	one month
Anti-drug antibodies	Development of human anti-monoclonal antibodies following treatment	one month

Collaborators and Investigators

• Sponsor: Implicit Bioscience
• Collaborators: Royal Brisbane and Women's Hospital
• Investigators: Principal Investigator: Robert D. Henderson, MBBS, Royal Brisbane and Women's Hospital

Publications and helpful links

General Publications

• Henderson RD, Agosti JM, McCombe PA, Thorpe K, Heggie S, Heshmat S, Appleby MW, Ziegelaar BW, Crowe DT, Redlich GL. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021 Oct 22;100(42):e27421. doi: 10.1097/MD.0000000000027421.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2017
• Primary Completion (Actual): April 18, 2018
• Study Completion (Actual): December 30, 2018

Study Registration Dates

• First Submitted: March 9, 2018
• First Submitted That Met QC Criteria: March 27, 2018
• First Posted (Actual): April 4, 2018

Study Record Updates

• Last Update Posted (Actual): March 14, 2019
• Last Update Submitted That Met QC Criteria: March 12, 2019
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: monoclonal antibody; amyotrophic lateral sclerosis; motor neurone disease; IC14 [anti-CD14 (cluster of differentiation 14) monoclonal antibody]; anti-CD14
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuromuscular Diseases; Neurodegenerative Diseases; Spinal Cord Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Sclerosis; Motor Neuron Disease; Amyotrophic Lateral Sclerosis
• Other Study ID Numbers: ALS01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No